A provider's guide to primary myelofibrosis: pathophysiology, diagnosis, and management.
Garmezy B, Schaefer JK, Mercer J, Talpaz M.
Blood Rev. 2021 Jan;45:100691. doi: 10.1016/j.blre.2020.100691. Epub 2020 Apr 7.
Primary myelofibrosis and its targeted therapy.
Shantzer L, Berger K, Pu JJ.
Ann Hematol. 2017 Apr;96(4):531-535. doi: 10.1007/s00277-016-2785-9. Epub 2016 Aug 19.
Distinguishing autoimmune myelofibrosis from primary myelofibrosis.
Marcellino B, El Jamal SM, Mascarenhas JO.
Clin Adv Hematol Oncol. 2018 Sep;16(9):619-626.
Fibrogenesis in Primary Myelofibrosis: Diagnostic, Clinical, and Therapeutic Implications.
Nazha A, Khoury JD, Rampal RK, Daver N.
Oncologist. 2015 Oct;20(10):1154-60. doi: 10.1634/theoncologist.2015-0094. Epub 2015 Aug 24.
Myeloproliferative Neoplasms: Contemporary Review and Molecular Landscape.
Mahmud M, Vasireddy S, Gowin K, Amaraneni A.
Int J Mol Sci. 2023 Dec 12;24(24):17383. doi: 10.3390/ijms242417383.
Primary myelofibrosis: update on definition, pathogenesis, and treatment.
Abdel-Wahab OI, Levine RL.
Annu Rev Med. 2009;60:233-45. doi: 10.1146/annurev.med.60.041707.160528.
About primary myelofibrosis.
Ozsoylu S.
Eur J Haematol. 1988 Nov;41(5):509.
Mutational spectrum defines primary and secondary myelofibrosis.
Mills KI, McMullin MF.
Haematologica. 2014 Jan;99(1):2-3. doi: 10.3324/haematol.2013.101279.
Post-ET and Post-PV Myelofibrosis: Updates on a Distinct Prognosis from Primary Myelofibrosis.
Passamonti F, Mora B, Barraco D, Maffioli M.
Curr Hematol Malig Rep. 2018 Jun;13(3):173-182. doi: 10.1007/s11899-018-0453-y.
[Primary myelofibrosis with double mutation in U2AF1].
Maeyama K, Nagaharu K, Ino K, Sugimoto Y, Tawara I, Kawakami K.
Rinsho Ketsueki. 2024;65(1):30-34. doi: 10.11406/rinketsu.65.30.
